Guardant Health: MolDX administrator grants coverage for Guardant Reveal

Guardant Health (GH) announced that Palmetto GBA, a Medicare administrative contractor that administers the Molecular Diagnostics Services program or MolDX , granted coverage for the Guardant Reveal test to monitor for disease recurrence in patients with colorectal cancer CRC following curative intent therapy. Guardant Reveal, which runs on Guardant’s Smart Liquid Biopsy platform, is a blood test that uses epigenomic or methylation analysis to detect circulating tumor DNA ctDNA , a marker of minimal residual disease MRD , to predict cancer recurrence, helping to guide clinical decisions after surgery or chemotherapy. As a result of this decision, the Guardant Reveal test is now covered for use in the CRC surveillance setting after curative intent treatment. This represents an expansion from the prior Medicare coverage of Guardant Reveal testing for CRC in the early post-surgical setting only.